From: Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement
Variables | Normal Lp-PLA2 (n = 196) | Elevated Lp-PLA2 (n = 130) | P value |
---|---|---|---|
Age (years) | 57.4 ± 11.6 | 58.3 ± 13.2 | 0.115 |
Male (%) | 130 (66.3) | 85 (65.4) | 0.172 |
Ever smoking (%) | 103 (52.6) | 71 (54.6) | 0.168 |
HTN (%) | 105 (53.6) | 72 (55.4) | 0.138 |
DM (%) | 40 (20.4) | 28 (21.5) | 0.144 |
Family history (%) | 82 (41.8) | 58 (44.6) | 0.126 |
BMI (Kg/m2) | 25.4 ± 2.7 | 25.6 ± 2.2 | 0.278 |
CHOL (mmol/L) | 4.64 ± 1.08 | 4.78 ± 1.12 | 0.389 |
LDL-C (mmol/L) | 2.46 ± 0.79 | 2.68 ± 0.93 | 0.175 |
HDL-C (mmol/L) | 1.08 ± 0.36 | 1.07 ± 0.33 | 0.405 |
Log TG (mmol/L) | 0.17 ± 0.22 | 0.15 ± 0.21 | 0.141 |
Lp(a) (mg/dL) | 27.6 ± 8.4 | 32.4 ± 10.5 | 0.062 |
CREA (umol/L) | 93.5 ± 36.4 | 97.4 ± 32.8 | 0.804 |
BUN (mmol/L) | 6.7 ± 1.3 | 7.1 ± 1.6 | 0.628 |
Uric acid (umol/L) | 394.5 ± 122.5 | 377.6 ± 112.8 | 0.767 |
Hs-CRP (mg/L) | 4.11 ± 0.92 | 4.07 ± 0.86 | 0.276 |
Lp-PLA2 (ng/mL) | 123.2 ± 33.6 | 336.8 ± 85.4 | <0.001 |
LVEF (%) | 65.4 ± 12.6 | 63.8 ± 10.2 | 0.446 |
FS (%) | 28.5 ± 3.3 | 27.2 ± 3.6 | 0.308 |
Anti-DM (%) | 34 (85.0) | 24 (85.7) | 0.147 |
Anti-HTN (%) | 98 (93.3) | 67 (93.1) | 0.325 |